Anupam Rama, an analyst from J.P. Morgan, has initiated a new Buy rating on Vor Biopharma (VOR).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Anupam Rama has given his Buy rating due to a combination of factors that highlight the potential of Vor Biopharma’s telitacicept. The drug, a dual APRIL/BAFF inhibitor, is seen as significantly de-risked due to late-stage data from China, where it is already approved or in the regulatory process for Myasthenia Gravis (MG) and primary Sjögren’s Disease (pSD). Vor Biopharma has strategically chosen to focus on global indications that have substantial unmet needs and less competition, which positions telitacicept as a promising candidate for blockbuster sales in the U.S. market.
Moreover, Rama points out a valuation disconnect in VOR shares, suggesting that the market has not fully appreciated the probability-adjusted value of telitacicept in MG and pSD. As global studies progress and the financing situation improves, there is potential for the stock to increase in value. The analyst also notes that resolving cash constraints could remove a sentiment overhang, allowing the company to focus on the fundamentals of its promising product. The December 2026 price target of $43 reflects these considerations, with additional upside potential as the MG and pSD programs advance.
Rama covers the Healthcare sector, focusing on stocks such as Oric Pharmaceuticals, IDEAYA Biosciences, and Olema Pharmaceuticals. According to TipRanks, Rama has an average return of 17.1% and a 52.02% success rate on recommended stocks.